EGEN Aims to Use 'Bottom-Up' Approach for RNAi Drug-Development Programs

Last week, EGEN said it had extended a collaboration with SurModics to develop a controlled-release system for siRNA delivery. As with its other programs, the company plans to let the delivery route determine the indications it pursues.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.